Follicular lymphoma (FL), commonly referred to as an indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). FL has an incidence of ∼15,000 new cases/year in the United States, and the median age is 60 years old at diagnosis [1]. Median survival rates have historically reported to be in the range of 8 to 10 years. Although the availability of newer agents, including the monoclonal antibody rituximab, has dramatically improved outcome and survival, FL remains incurable with standard therapy [2].
No takes yet. Share an insight, caveat, or question.
Sehn et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: